A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

NCT04207918 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Chemoradiotherapy
Nimotuzumab
Unresectable Malignant Neoplasm

Interventions

RADIATION: Radiotherapy
DRUG: Nimotuzumab
DRUG: S-1

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences